SPRO / All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal

The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to thi more_horizontal

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compare more_horizontal

Spero Therapeutics shares soared after the clinical-stage biopharmaceutical company announced that it has received special protocol approval from the more_horizontal

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Ted Jenkins – Vice President, more_horizontal

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compare more_horizontal

Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market. more_horizontal